AbCellera Biologics Inc Share Price Today: Live Updates & Key Insights

AbCellera Biologics Inc share price today is $7.6772, up 6.13%. The stock opened at $6.68 against the previous close of $6.53, with an intraday high of $6.99 and low of $6.35.

AbCellera Biologics Inc Share Price Chart

AbCellera Biologics Inc

us-stock
To Invest in {{usstockname}}
us-stock

AbCellera Biologics Inc Share Price Performance

$7.6772 0.0613(6.13%) ABCL at 10 Aug 2026 05:40 PM Biotechnology
Lowest Today 6.35
Highest Today 6.99
Today’s Open 6.68
Prev. Close 6.53
52 Week High 8.44
52 Week Low 2.75
Day’s Range: Low 6.35 High 6.99
52-Week Range: Low 2.75 High 8.44
1 day return -
1 Week return +19.15
1 month return -4.73
3 month return +31.96
6 month return +115.37
1 year return +53.76
3 year return +15.1
5 year return -57.24
10 year return -

AbCellera Biologics Inc Institutional Holdings

Baker Bros Advisors LP 9.91

Capital World Investors 4.38

American Funds SMALLCAP World A 4.33

Two Sigma Investments LLC 3.46

TD Waterhouse Canada Inc 3.13

UBS Asset Mgmt Americas Inc 2.48

UBS Group AG 1.38

ArrowMark Colorado Holdings, LLC (ArrowMark Partners) 1.34

BlackRock Inc 1.32

Driehaus Capital Management LLC 1.32

The Goldman Sachs Group Inc 1.23

Bank of America Corp 0.98

Jefferies Financial Group Inc 0.90

Alyeska Investment Group, L.P. 0.85

Tudor Investment Corp Et AL 0.74

Morgan Stanley - Brokerage Accounts 0.73

ACATIS Datini Valueflex Fonds A 0.61

UBS Lux Dgtl Hlth Eq Fd seeding P acc 0.59

Guardian Partners Inc. 0.59

iShares Biotechnology ETF 0.57

Renaissance Technologies Corp 0.49

Citadel Advisors Llc 0.45

Millennium Management LLC 0.42

HRT FINANCIAL LLC 0.40

T. Rowe Price New Horizons 0.35

US Small-Cap Growth II Equity Comp 0.35

Counterpoint Quantitative Equity ETF 0.34

DNB Fund Disrpt Opps A EUR Acc 0.21

Heptagon Driehaus US Micro Cap Eq C$ Acc 0.21

State Street® SPDR® Ptf Dev Wld exUS ETF 0.19

iShares Genomics Immnlgy & Hlthcr ETF 0.17

T. Rowe Price New Horizons Tr-A 0.15

American Funds IS® SMALLCAP World 1 0.12

BlackRock Advantage Small Cap Core Instl 0.11

iShares Healthcare Innov ETF USD Acc 0.10

Driehaus Micro Cap Growth USD 0.08

iShares Nasdaq US Biotech ETF USD Acc 0.08

Driehaus Micro Cap Growth USD 0.08

Fidelity Nasdaq Composite Index 0.06

State Street® SPDR® S&P® Intl Sm Cp ETF 0.05

AbCellera Biologics Inc Market Status

Strong Buy: 6

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

AbCellera Biologics Inc Fundamentals

Market Cap 1994.10 M

PB Ratio 1.8588

PE Ratio 0.0

Enterprise Value 1379.14 M

Total Assets 1356.95 M

Volume 6823454

AbCellera Biologics Inc Company Financials

Annual Revenue FY25:75128000 75.1M, FY23:50391000 50.4M, FY22:485424000 485.4M, FY21:11611543 11.6M, FY20:233155000 233.2M

Annual Profit FY25:null 0.0M, FY23:48837000 48.8M, FY22:418988000 419.0M, FY21:11611543 11.6M, FY20:206012000 206.0M

Annual Net worth FY25:-146412000 -146.4M, FY23:-129141000 -129.1M, FY22:158519000 158.5M, FY21:-2210696 -2.2M, FY20:118918000 118.9M

Quarterly Revenue Q2/2026:4050000 4.1M, Q1/2026:8315000 8.3M, Q4/2025:44852000 44.9M, Q3/2025:8955000 9.0M, Q2/2025:17084000 17.1M

Quarterly Profit Q2/2026:4050000 4.1M, Q1/2026:-340000 -0.3M, Q4/2025:-59438000 -59.4M, Q3/2025:8955000 9.0M, Q2/2025:10025000 10.0M

Quarterly Net worth Q2/2026:-55427000 -55.4M, Q1/2026:-43165000 -43.2M, Q4/2025:-8945000 -8.9M, Q3/2025:-57119000 -57.1M, Q2/2025:-34727000 -34.7M

About AbCellera Biologics Inc & investment objective

Company Information AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Organisation Biotechnology

Employees 562

Industry Biotechnology

CEO Dr. Carl L.G. Hansen Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

AbCellera Biologics Inc FAQs

What is the share price of AbCellera Biologics Inc today?

The current share price of AbCellera Biologics Inc is $7.6772.

Can I buy AbCellera Biologics Inc shares in India?

Yes, Indian investors can buy AbCellera Biologics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy AbCellera Biologics Inc shares in India?

You can easily invest in AbCellera Biologics Inc shares from India by:

Can I buy fractional shares of AbCellera Biologics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of AbCellera Biologics Inc?

AbCellera Biologics Inc has a market cap of $1994.10 M.

In which sector does AbCellera Biologics Inc belong?

AbCellera Biologics Inc operates in the Biotechnology sector.

What documents are required to invest in AbCellera Biologics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of AbCellera Biologics Inc?

The PE ratio of AbCellera Biologics Inc is N/A and the PB ratio is 1.86.